Drotrecogin alfa (activated) treatment in severe sepsis from the global open-label trial ENHANCE: Further evidence for survival and safety and implications for early treatment* - Concepedia

Concepedia

Publication | Closed Access

Drotrecogin alfa (activated) treatment in severe sepsis from the global open-label trial ENHANCE: Further evidence for survival and safety and implications for early treatment*

320

Citations

10

References

2005

Year

Jean‐Louis Vincent, Gordon R. Bernard, Richard Beale, Christopher J. Doig, Christian Putensen, Jean-François Dhainaut, Antonio Artigas, Roberto Fumagalli, William L. Macias, Theressa J. Wright,

Critical Care Medicine

Abstract

ENHANCE provides supportive evidence for the favorable benefit/risk ratio observed in PROWESS and suggests that more effective use of drotrecogin alfa (activated) might be obtained by initiating therapy earlier.

References

	Year	Citations

Page 1